PLoS ONE (Jan 2022)

Readmission rates and risk factors for readmission after transcatheter aortic valve replacement in patients with end-stage renal disease

  • Dae Yong Park,
  • Seokyung An,
  • Jonathan M. Hanna,
  • Stephen Y. Wang,
  • Ana S. Cruz-Solbes,
  • Ajar Kochar,
  • Angela M. Lowenstern,
  • John K. Forrest,
  • Yousif Ahmad,
  • Michael Cleman,
  • Abdulla Al Damluji,
  • Michael G. Nanna

Journal volume & issue
Vol. 17, no. 10

Abstract

Read online

Objectives We sought to examine readmission rates and predictors of hospital readmission following TAVR in patients with ESRD. Background End-stage renal disease (ESRD) is associated with poor outcomes following transcatheter aortic valve replacement (TAVR). Methods We assessed index hospitalizations for TAVR from the National Readmissions Database from 2017 to 2018 and used propensity scores to match those with and without ESRD. We compared 90-day readmission for any cause or cardiovascular cause. Length of stay (LOS), mortality, and cost were assessed for index hospitalizations and 90-day readmissions. Multivariable logistic regression was performed to identify predictors of 90-day readmission. Results We identified 49,172 index hospitalizations for TAVR, including 1,219 patients with ESRD (2.5%). Patient with ESRD had higher rates of all-cause readmission (34.4% vs. 19.2%, HR 1.96, 95% CI 1.68–2.30, pConclusion Patients with ESRD undergoing TAVR have higher mortality and increased cost associated with their index hospitalization and are at increased risk of readmission within 90 days following TAVR.